Last week, stock markets were rocked by a wave of sell recommendations. Many analysts and experts recommended selling stocks and investing in safer investments.
– On our own behalf –
Tip: Trade your stocks now for €0.00 at finanzen.net zero! Find out here
11th place: The ranking
Investors who want to buy or sell stocks often consult analyst opinions. In the last trading week, numerous experts again advised getting out of stocks. These shares were recommended for sale by the analysts.
Source: finanzen.net, image: SergeyP / Shutterstock.com
10th place: Apple
The analysis firm Jefferies has lowered the price target for Apple from $205.16 to $203.07 and left the rating at “Underperform”. For analysis
Source: finanzen.net, Image: Marek Szandurski / Shutterstock.com
9th place: DHL
The major Swiss bank UBS has left the rating for DHL Group at “Sell” with a price target of 36 euros. For analysis
Source: finanzen.net, image: AIF
8th place: Swiss Re
The Canadian bank RBC has downgraded Swiss Re from “Sector Perform” to “Underperform” and lowered its price target from 143 to 125 francs. For analysis
Source: finanzen.net, image: Swiss Re
7th place: Nordex
The Canadian bank RBC has left the rating for Nordex at “Underperform” with a price target of 18.50 euros. For analysis
Source: finanzen.net, image: Lukassek / Shutterstock.com
6th place: Brenntag
The US bank JPMorgan has lowered the price target for Brenntag from 51.50 to 45.40 euros and left the rating at “Underweight”. For analysis
Source: finanzen.net, image: Brenntag AG
5th place: DocMorris
According to an interim report for the third quarter, the major Swiss bank UBS left the rating for DocMorris at “Sell” with a price target of 5.90 francs. For analysis
Source: finanzen.net, Image: Tobias Zeit 2016 / DocMorris
4th place: Nemetschek
The US bank JPMorgan left Nemetschek’s rating at “Underweight” with a price target of 100 euros ahead of the third quarter figures. For analysis
Source: finanzen.net, image: Nemetschek Group
3rd place: AstraZeneca
Deutsche Bank Research downgraded AstraZeneca from Hold to Sell and lowered its price target from 11,000 pence to 10,500 pence. For analysis
Source: finanzen.net, Image: Oli Scarff/Getty Images
2nd place: Fresenius Medical Care
The US bank JPMorgan has left the rating for FMC at “Underweight” with a price target of 41.50 euros ahead of figures for the third quarter. For analysis
Source: finanzen.net, Image: Fresenius Medical Care
1st place: Carl Zeiss Meditec
The US bank JPMorgan has left the rating for Carl Zeiss Meditec at “Underweight” with a price target of 35.10 euros. For analysis
Source: finanzen.net, image: Carl Zeiss Meditec